Our results demonstrated that SFN suppressed the expression of TLR2 and TLR4 both at the mRNA and the protein levels, thus suggesting potential clinical applications against inflammation in COPD. The gene discussed is TLR4; the disease is chronic obstructive pulmonary disease.